Micronoma Announcements

 AACR 2023 presentation highlights noteworthy diagnostic performance potential using cell-free microbial DNA in diagnosing early-stage lung cancer April 19, 2023. San Diego, CA—Highlighting that cancer is no longer considered a sterile disease, Greg Sepich-Poore,...

Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifyingthe “infinite potential” of using microbiome markers to diagnose cancer.March 29, 2023. SAN DIEGO, Calif.--Based on an independent team of expert’srigorous evaluation of a broad...

The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy created to detect lung carcinomas in its earliest stagesJanuary 10, 2023. SAN DIEGO, Calif.–  Micronoma, the first biotech company developing early cancer detection with a microbiome-driven...

December 14, 2022. SAN DIEGO, Calif.-- Micronoma, the first biotech company offering early cancer detection using a microbiome-driven liquid biopsy platform, today announced that Sandrine Miller-Montgomery, Ph.D., Pharm.D., CEO and Co-founder of Micronoma will...

An international collaboration between the Weizmann Institute, UC San Diego, and Micronoma provides the most comprehensive characterization of fungi in cancer to date, discovering synergistic interactions with bacteria and furthering the role of mycobiome as an...

Todd Czerwinski will oversee the development and execution of market access, strategic partnerships and sales as the company rolls out its groundbreaking early cancer diagnosis platform SAN DIEGO, May 24, 2022 — Micronoma, the first cancer detection biotech company...

Microbiome-driven liquid biopsy company draws international recognition for using innovative technology to enable early cancer detection and improve chances of survivalSAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Micronoma, the first cancer detection biotech company to...

Machine learning and microbiome-driven liquid biopsy technology draws recognition for improving early cancer diagnosis and chances of survival August 2, 2021 ­­­­– San Diego, Calif. Micronoma, the first cancer detection biotech company to diagnose cancer  at an early...

Research uses circulating microbiome biomarkers, machine learning for early detection July 20, 2021 ­­­­– San Diego, Calif. Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage...

Jennifer Wargo, M.D., leads research on link between microbiome and cancer treatment and recently co-authored Science review with Micronoma founders  San Diego, Calif. (April 6, 2021) - San Diego, Calif. Micronoma, the first cancer detection biotech company that...

Investors more than double funding base for cancer microbiome diagnostic company to accelerate go-to-market timeline six months after seed February 17, 2021 -- San Diego, Calif. Micronoma, the first cancer detection biotech company that utilizes signals from the...

Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- Micronoma, an early stage cancer-detection start-up seeking to develop and commercialize a minimally-invasive, unique...

Micronoma Launches with $3 Million Seed Funding   First early cancer-detection company to use microbial biomarkers in diagnostics   San Diego, Calif. (August 12, 2020).  Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a...

Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
Systematic characterization of the cancer microbiome provides the opportunity to develop techniques that exploit non-human, microorganism-derived molecules in the diagnosis of a major human disease.

Micronoma will be presenting at Biocom this year. Go to Biocom Micronoma San Diego, CA, USA info@micronoma.com